Xeris Biopharma (NASDAQ:XERS) Stock Jumps 5.2% – Should You Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)’s stock price traded up 5.2% on Monday. The stock traded as high as $9.38 and last traded at $9.5750. 460,484 shares were traded during trading, a decline of 75% from the average session volume of 1,858,300 shares. The stock had previously closed at $9.10.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Wall Street Zen raised shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Barclays upped their price objective on shares of Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, Leerink Partners lifted their target price on Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a research report on Thursday, September 10th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $12.80.

Xeris Biopharma Stock Up 6.0%

The business’s fifty day moving average price is $8.36 and its 200 day moving average price is $7.18. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. The firm has a market capitalization of $1.76 billion, a PE ratio of -87.68 and a beta of 0.70.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The company had revenue of $92.10 million during the quarter, compared to analyst estimates of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. On average, equities research analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Beth Hecht sold 16,666 shares of the business’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $8.49, for a total transaction of $141,494.34. Following the completion of the sale, the insider directly owned 1,127,796 shares of the company’s stock, valued at $9,574,988.04. The trade was a 1.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 90,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $8.03, for a total value of $722,700.00. Following the sale, the insider owned 1,691,126 shares of the company’s stock, valued at approximately $13,579,741.78. The trade was a 5.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 224,998 shares of company stock valued at $1,847,219 in the last 90 days. 4.35% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Xeris Biopharma

Large investors have recently made changes to their positions in the business. Integrated Wealth Concepts LLC purchased a new stake in shares of Xeris Biopharma during the second quarter valued at approximately $74,000. Allworth Financial LP lifted its position in shares of Xeris Biopharma by 86.4% during the second quarter. Allworth Financial LP now owns 4,315 shares of the company’s stock worth $34,000 after purchasing an additional 2,000 shares during the last quarter. Allianz Asset Management GmbH acquired a new position in Xeris Biopharma in the second quarter worth about $314,000. Corient Private Wealth LP bought a new stake in Xeris Biopharma in the second quarter valued at about $1,458,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Xeris Biopharma in the second quarter valued at about $89,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc (NASDAQ:XERS) is a specialty pharmaceutical company focused on developing and commercializing therapies using proprietary formulation and drug-delivery technologies. Its platforms, including XeriSol and XeriJect, are designed to enable liquid or ready-to-use formulations of medicines that may otherwise require refrigeration, reconstitution, or administration by a healthcare professional.

The company’s commercial products include Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia; Keveyis (dichlorphenamide), an oral therapy for primary periodic paralysis; and Recorlev (levoketoconazole), an oral treatment for endogenous hypercortisolemia in adults with Cushing’s syndrome.